Pfizer Real World Evidence on clinical outcomes with Aztreonam-Avibactam (ATM-AVI)
Well-being, Health and Biomedical Discovery
Deadlines
Academic Unit: Inquire with unit
Memorial Deadline: Thursday 23rd, April 2026
External Deadline: Tuesday 28th, April 2026
Description
Pfizer External Research & Grants (ER&G) (formerly Global Medical Grants & Partnerships) supports the global healthcare community’s independent initiatives (e.g., research, quality improvement, or education) to improve patient outcomes in areas of unmet medical need that are aligned with Pfizer’s medical and/or scientific strategies.
Pfizer’s ER&G competitive grant program involves a publicly posted Request for Proposal (RFP) that provides detail regarding a general area of interest, sets timelines for review and approval, and uses an internal Pfizer review process to make final grant decisions. Organizations are invited to submit an application addressing the knowledge gaps as outlined in the specific RFP.
For all Investigator Sponsored Research (ISRs) and general research grants, the grant requester (and ultimately the grantee) is responsible for the design, implementation, sponsorship, and conduct of the independent initiative supported by the grant, including compliance with any regulatory requirements. Pfizer must not be involved in any aspect of study protocol or project development, nor the conduct or monitoring of the research program. An ISR grant request cannot be submitted for a study that has already commenced and was not originally supported by Pfizer.
Date RFP Issued: Mar 10, 2026
Geographic Scope: Countries where ATM-AVI is available (ex-US) and used in clinical practice at the time of RFP release, including but not limited to parts of EU, the United Kingdom, the Middle East, and selected Asia-Pacific markets.
Clinical Area: Infectious Disease – Bacterial
Link to full RFP: Real World Evidence on clinical outcomes with Aztreonam-Avibactam
Application Due Date: Apr 28, 2026
Specific Area of Interest: Potential applicants are requested to submit research proposals to study the below outcomes following treatment with ATM-AVI for adult patients with suspected or documented infections with aerobic gram negative organisms e.g. CRE-MBL, S. maltophilia.
- – Clinical effectiveness with ATM-AVI
- – Safety outcomes with ATM-AVI
- – Microbiological outcomes with ATM-AVI
- – Health Economic outcomes with ATM-AVI (in addition to any of the above)
Proposals may include data from special populations such as – immunocompromised (solid organ transplant or haemato-oncological patients).
Refer to complete details in the full RFP document. If you have questions regarding this RFP, please direct them in writing to the Grant Officer, Talita Honorato-Rzeszewicz (Talita.honorato-rzeszewicz@pfizer.com).